Soligenix shares fall 5.59% premarket after announcing long-term stability of ebolavirus vaccines.

Soligenix, Inc. dropped 5.59% in premarket trading. The company announced the publication of a study demonstrating the long-term stability of its ebolavirus vaccines using the ThermoVax® platform. The vaccines, formulated in a single vial, showed no change in potency after two years of storage at high temperatures, indicating the effectiveness of the company's technology.